Email your doctor to beat gout: new trial tests remote care

NCT ID NCT04733079

First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 35 times

Summary

This study tests whether regular email communication between gout patients and their doctors can help lower uric acid levels more effectively than standard care. 204 adults with confirmed gout will either follow usual care or use a secure messaging system to adjust their medication dose until their uric acid target is reached. The goal is to see if this remote, treat-to-target approach can improve gout control and reduce flares.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERURICEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hopital LARIBOISIERE - Rhumatologie

    Paris, 75010, France

  • Rhumathology department

    Paris, Île-de-France Region, 75010, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cleanweb electronic messaging ePro

What this could lead to

If successful, this could offer a simple, remote way to manage gout effectively, reducing flares and complications.

What could go wrong

This is a relatively small, early-stage trial comparing email follow-up to usual care. The approach may not work for everyone, and results may not apply to all gout patients.

Conditions

The condition(s) this trial relates to.

gout Hyperuricemia Patient Compliance rheumatic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.